Abstract:Pulmonary hypertension (PH) is a pulmonary vascular disease characterized by a high mortality rate. Pulmonary arterial endothelium cells (PAECs) serve as a primary sensor of various environmental cues, such as shear stress and hypoxia, but PAEC dysfunction may trigger vascular remodeling during the onset of PH. This study was aimed to illustrate the role of SIRT7 in endothelial dysfunction during PH, and explore the potential therapeutic strategy for PH. SIRT7 levels were measured in human and murine experimental PH samples. Bioinformatic analysis, immunoprecipitation, and deacetylation assay was used to identify the association between SIRT7 and Krüpple-like factor 4 (KLF4), a key transcription factor essential for EC homeostasis. Sugen5416+hypoxia (SuHx)-induced PH mouse models and cell cultures were used for the study of the therapeutic effect of SIRT7 for PH. SIRT7 level was significantly reduced in lung tissues and PAECs from PH patients and the SuHx-induced PH mouse model as compared with healthy controls. Pulmonary endothelium-specific depletion of Sirt7 increased right ventricular systolic pressure and exacerbated right ventricular hypertrophy in the SuHx-induced PH model. At the molecular level, we identified KLF4 as a downstream target of SIRT7, which deacetylated KLF4 at K228 and inhibited the ubiquitination-proteasome degradation. Thus, the SIRT7/KLF4 axis maintained PAEC homeostasis by regulating proliferation, migration, and tube formation. PAEC dysfunction was reversed by adeno-associated virus type 1 vector mediated endothelial overexpression of Sirt7 or supplementation with NAD + intermediate nicotinamide riboside which activated Sirt7; both approaches successfully reversed PH phenotypes. The SIRT7/KLF4 axis ensures PAEC homeostasis, and pulmonary endothelium-specific SIRT7 targeting might constitute a PH therapeutic strategy. Pulmonary endothelial cell dysfunction is pivotal in vascular remodeling process during pulmonary hypertension pathogenesis. We identified a SIRT7/KLF4 axis essential for pulmonary endothelial homeostasis, however compromised in pulmonary hypertension patients and animal models. Pulmonary endothelium-specific Sirt7 gene delivery or treatment with NAD + precursor reversed PH phenotypes, providing a new therapeutic strategy for PH. In normal pulmonary artery endothelial cells, SIRT7 deacetylates KLF4 at K228 to maintain its protein stability, promotes endothelial homeostasis and pulmonary vascular function. During pulmonary hypertension pathogenesis, SIRT7 was reduced, resulted in increased acetylation of KLF4, promoting its ubiquitination and degradation in pulmonary endothelial cells. The ultimate endothelial dysfunction contributes to vascular remodeling and accelerated pulmonary hypertension.

What problem does this paper attempt to address?

The problem this paper attempts to address is the exploration of the role of SIRT7 in pulmonary hypertension (PH) and its potential therapeutic strategies. Specifically, the study found that the expression of SIRT7 in pulmonary artery endothelial cells (PAECs) is significantly reduced, and the decrease in SIRT7 is closely related to the development of PH. Through the use of mouse models and cell experiments, researchers demonstrated that specifically targeting SIRT7 in lung endothelial cells can improve the symptoms of PH, revealing the relationship between SIRT7 and its downstream target KLF4. This indicates that SIRT7 maintains PAEC homeostasis by deacetylating KLF4. This finding provides new strategies for the treatment of PH.

Endothelium-specific SIRT7 targeting ameliorates pulmonary hypertension through KLF4 deacetylation